ISPOR Europe 2024

Drug Development and Launch Timeline Analysis Across 6 High-Income Countries: From Pivotal Trial to HTA

Explore our timeline analysis of drug development and market entry across six high-income countries, presented at ISPOR EU 2024.

Determinants of Added Benefit Ratings in Germany: An Econometric Analysis of Assessments From the Federal Joint Committee Between 2012 and 2024

Examine our econometric analysis of added benefit ratings by Germany’s Federal Joint Committee from 2012 to 2024, presented at ISPOR EU 2024.

Improving Access to Innovative Therapies for Rare Bleeding Disorders: Evidence From High Income Countries

Explore our ISPOR EU 2024 poster discussing strategies to enhance access to innovative therapies for rare bleeding disorders in high-income countries.

A Quantitative Assessment of the Economic Decision Drivers Outlined in HTA Outcomes Through Stratification and Sentiment Analysis: Evidence From Canada, England, Scotland, and Sweden

Discover our quantitative assessment of economic decision drivers in HTA outcomes across four countries, presented at ISPOR EU 2024.

Sentiment Analysis of Clinical Evaluations in HTA: Evidence From Canada, England, Scotland, Sweden, France, and Germany

Dive into our ISPOR EU 2024 poster analysing sentiment in clinical evaluations across multiple HTA agencies in different countries.

Diverging Relative Clinical Benefit Assessment Across HAS and G-BA: A Forecast for EU HTA in Oncology Drugs.

Explore our latest poster presented at ISPOR EU 2024, examining diverging relative clinical benefit assessments between HAS and G-BA for oncology drugs, and its implications for the evolving EU HTA landscape.

Reassessment Dynamics of Orphan Drugs in Germany’s Benefit Assessment Process.

Explore our ISPOR EU 2024 poster on the evolving reassessment dynamics of orphan drugs within Germany's benefit assessment framework, and how these processes impact patient access and market sustainability.

Leveraging Machine Learning for Predicting Health Technology Assessment Outcomes.

Discover our poster presented at ISPOR EU 2024, which explores the application of machine learning to predict HTA outcomes and improve decision-making accuracy.

First to Launch, First to Falter? An Investigation Into the Clinical Benefits and HTA Outcomes for First-in-Class Drugs

Explore the nuanced relationship between market entry timing and HTA outcomes for first-in-class drugs in our ISPOR EU 2024 poster.

Nov 17, 2024

Read article

